Share Information

Färna Invest AB innehar över 90 procent av aktierna i ChromoGenics AB och begär avnotering samt påkallar tvångsinlösen av resterande aktier

Färna Invest AB (”Färna Invest”) offentliggjorde den 23 maj 2024 ett rekommenderat offentligt uppköpserbjudande till aktieägarna i ChromoGenics AB (”ChromoGenics” eller ”Bolaget”) att överlåta samtliga aktier i ChromoGenics till Färna Invest för 10 kronor kontant per aktie (”Erbjudandet”). Färna Invest kontrollerade cirka 87,9 procent av det totala antalet aktier och röster i Bolaget efter Erbjudandets avslutande.

Färna Invest meddelar idag att Färna Invest har förvärvat ett sådant ytterligare antal aktier i Bolaget att Färna Invest innehar över 90,0 procent av det totala antalet aktier och röster i ChromoGenics. Inga aktier har förvärvats till högre pris än priset per aktie i Erbjudandet.

Färna Invest har mot bakgrund av detta påkallat tvångsinlösen i enlighet med aktiebolagslagen avseende resterande aktier i ChromoGenics, samt begärt att ChromoGenics ansöker om avnotering från Nasdaq First North Growth Market.

Färna Invest AB
Styrelsen

Informationen lämnades för offentliggörande den 10 september 2024 kl. 14.15 (CEST).

För ytterligare information, vänligen kontakta
Dan Bergström eller Anton Nordén, Penser by Carnegie

Telefonnummer: 08-5886 88 00

E-postadress: budfiab@carnegie.se

Bifogade filer
Färna Invest AB innehar över 90 procent av aktierna i ChromoGenics AB och begär avnotering samt påkallar tvångsinlösen av resterande aktier

Press release

https://chromogenics.com/wp-content/uploads/2024/09/24-09-13-Pressmeddelande-ChromoGenic-avnotering.pdf

https://chromogenics.com/wp-content/uploads/2024/09/24-09-16-Avnotering-av-ChromoGenics-AB.pdf

Färna Invest AB buy-out offer

ChromoGenics AB (publ) is a “Euroclear company” and the shares are electronically registered, the share register is kept by Euroclear Sweden AB, Klarabergsviadukten 63, 111 64 Stockholm.

The company’s shares are listed on Nasdaq First North Growth Market since March 23, 2017.

All shares are of the same class, have equal rights to share the Company’s assets and profits and have one vote each without any special limitations.

Share capital on April 5, 2024 amounted to 36 469 680,50 SEK distributed over 6 630 851 shares.

ChromoGenics’ shares and warrants are traded on Nasdaq First North Growth Market.

Trading Information

Share
ISIN-code: SE0014730719

LEI-code: 549300ULKN252K60BG25

Short name: CHRO

Only one share category exists.

Dividend Policy

In Swedish companies, the dividend must be proposed by the Board and decided by the Annual General Meeting in accordance with the Companies Act and the Articles of Association.

In consideration of proposals for future dividends, the Board will consider several factors, including the Company’s operations, operating profit and financial position, current and expected liquidity needs, expansion plans, contractual constraints and other significant factors.

ChromoGenics is in a development and expansion phase and therefore no dividend has ever been paid. At present, the Board intends to continue to allow the Company to balance any profits to finance the growth and operation of the business and consequently does not predict that any cash dividends will be paid in the foreseeable future.

Ownership

Each share in ChromoGenics entails one (1) vote at the Annual General Meeting.
Largest owners as of May 31, 2024.

Warrants

The warrants of series TO 6, with short name CHRO TO6 and ISIN code SE0020357507, are to be traded on Nasdaq First North Growth Market. See further pressrelease HERE.

Certified Adviser

Vator Securities AB has been appointed Certified Adviser for ChromoGenics.

Vator Securities AB
Tel: +46 (0)8 5800 6599
E-mail: ca@vatorsec.se